Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of daratumumab plus GDP in relapsed or refractory CD38-positive nodal peripheral T-cell lymphomas
2018-002644-91Phase 2Completed
- Sponsor
- Fondazione Italiana Linfomi
- Start
- May 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daratumumab, gemcitabine, dexamethasone and cisplatin in peripheral T-cell lymphoma (PTCL), angioimmunoblastic T-cell lymphoma (AITL) and follicular T-cell lymphoma (FTCL), sponsored by Fondazione Italiana Linfomi. Primary endpoint: Complete Response Rate. Started May 2021; status: completed.
02
Drugs
daratumumabgemcitabinedexamethasonecisplatin
03
Conditions
peripheral T-cell lymphoma (PTCL)angioimmunoblastic T-cell lymphoma (AITL)follicular T-cell lymphoma (FTCL)
Beyond the preview
Go deeper on 2018-002644-91.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002644-91.